Tilmacoxib

Tilmacoxib is a nonsteroidal anti-inflammatory drug (NSAID) that was developed by the pharmaceutical company SK Chemicals. It is a COX-2 inhibitor, which means it works by blocking the enzyme cyclooxygenase-2 (COX-2), thereby reducing the production of prostaglandins, chemicals that cause inflammation and pain in the body. Tilmacoxib was designed to be used for the treatment of osteoarthritis, rheumatoid arthritis, and acute pain.

Pharmacology

Tilmacoxib is a selective COX-2 inhibitor, which means it specifically targets the COX-2 enzyme without affecting the COX-1 enzyme. This selectivity is believed to reduce the risk of gastrointestinal side effects that are common with non-selective NSAIDs, which inhibit both COX-1 and COX-2. However, like all COX-2 inhibitors, tilmacoxib may increase the risk of heart attack and stroke.

Clinical Trials

Tilmacoxib has undergone clinical trials to evaluate its safety and efficacy in treating osteoarthritis, rheumatoid arthritis, and acute pain. However, the results of these trials have not been published in peer-reviewed medical journals.

Availability

As of 2021, tilmacoxib is not available for use in the United States, the European Union, or most other countries. It is not known whether SK Chemicals plans to seek regulatory approval for the drug in these or other jurisdictions.

See Also

• Nonsteroidal anti-inflammatory drug
• COX-2 inhibitor
• Cyclooxygenase
• Prostaglandin
• Osteoarthritis
• Rheumatoid arthritis
• Acute pain

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia

Tilmacoxib

• 
  Chemical structure of Tilmacoxib
• 
  Ball-and-stick model of Tilmacoxib